Skip to content

Potential Effects of AHCC on Immune Function and Stress Responses

Written by Tabish Mehraj, PhD. In this study, AHCC® increased parasympathetic activity at rest and sympathetic activity during mental stress. In individuals experiencing chronic mental stress, it improved self-reported sleep initiation and maintenance and increased natural killer (NK) cell activity. These preliminary findings suggest that AHCC may influence selected physiological stress responses and potentially benefit mood regulation.

woman holding headStress can impair sleep, mood, concentration, immunity, and overall well-being. Chronic stress may also promote systemic inflammation and increase the risk of cardiovascular and autoimmune diseases. AHCC® (Amino Up Chemical Co., Ltd., Sapporo, Japan) is a standardized functional ingredient derived from cultured shiitake mushroom mycelia. Previous studies found that AHCC® helped stabilize stress-related hormones and glucose in immobilized rats, and reduced severe anxiety in patients with unresectable prostate cancer. Although earlier research suggested that AHCC® may influence immune function, its effects on everyday physical and mental stress remained unclear. This study evaluated whether AHCC® could support the body’s response to short-term stress, promote calmness at rest, and enhance immune function.

This study consisted of four small studies involving healthy young adults. Participants took 3 g of AHCC® daily for 5 to 14 days. In three studies, AHCC® was compared with a placebo, and neither participants nor researchers knew which product was being taken at the time. The researchers measured changes in the body’s stress response after standing up or completing a timed arithmetic task. They also assessed feelings, sleep, tiredness, task performance, and natural killer cell activity. The last study selected seven volunteers with questionnaire scores suggesting mild depressive symptoms and compared their AHCC® and placebo periods.

Results/ Key Findings

  • AHCC® (3 g/day) significantly increased sympathetic nervous activity (5.62 ± 3.50 vs. 2.63 ± 1.65; P < .05) in 5 days among 8 healthy volunteers compared to placebo.
  • AHCC® (3 g/day) significantly increased parasympathetic nervous activity (807.4 ± 518.8 vs. 500.9 ± 473.8; P < .01) in 7 days among 5 volunteers compared to placebo.
  • After 7 days of AHCC® intake, anger/hostility significantly improved (P < .05), while sleep difficulties and fatigue showed trends toward improvement (P = .080 and .099, respectively).
  • In 17 healthy volunteers, 7 days of AHCC® significantly increased sympathetic nervous activity during mental stress (3.78 ± 2.03 to 4.96 ± 3.67; P < .05), with no significant change in parasympathetic activity.
  • 7 volunteers with mild depressive symptoms, 14 days of AHCC® significantly improved reported sleep initiation and maintenance (P < .05), increased correct answers in the arithmetic test (P < .01), and increased NK cell activity from 28.16 ± 10.96% to 37.84 ± 15.92% (P = 0.020). No adverse reactions were reported.

A key strength of this research is its use of multiple assessment methods rather than relying solely on participants’ self-reported experiences. Across the four studies, researchers evaluated responses to physical and mental stress tests, daily well-being questionnaires, sleep assessments, a work-related task, and measures of immune activity. The crossover design, in which participants received both AHCC® and placebo at different times, also allowed each participant to serve as their own control, helping to account for individual differences. The four studies used small, partly overlapping samples composed mostly of young, healthy adults, with only 5 to 17 participants per study. One study was open-label, meaning participants knew they were receiving AHCC®. Several outcomes were assessed using self-reported questionnaires, and some findings reflected trends rather than statistically significant effects.

These preliminary findings suggest that AHCC® may influence the body’s responses to physical and mental stress, support relaxation under resting conditions, and enhance certain measures of immune activity in individuals with questionnaire scores suggesting mild depressive symptoms. The studies also reported early indications of improvements in sleep, fatigue, mood, and performance on a concentration task. Nevertheless, the limited sample sizes, short study durations, and preliminary nature of the findings do not support recommending AHCC® as a treatment for depression or other medical conditions. Larger, independent, and longer-term clinical trials involving more diverse populations are needed to confirm these findings, clarify optimal dosing, further evaluate safety, and determine whether changes observed in physiological and laboratory measures translate into meaningful benefits in everyday life.

Click here to read the full text study.

Posted November 16, 2026.

Dr. Tabish Mehraj is a pharmaceutical scientist with expertise in pharmaceutics, drug delivery, and formulation development. She earned her PhD in Pharmaceutical Sciences from the University of Mississippi, where her research focused on the formulation, optimization, and characterization of lipid-based nanocarriers for targeted liver delivery of antimalarial therapeutics. Dr. Mehraj has also served as an ORISE Fellow at the U.S. Food and Drug Administration (FDA), where she evaluated the effects of formulation and process design on the quality and performance of intravaginal drug delivery systems and developed bio-relevant in vitro drug release testing methods. She has teaching experience in pharmaceutical and life sciences courses and has authored peer-reviewed publications, book chapters, and conference presentations. Dr. Mehraj is an active member of the American Association of Pharmaceutical Scientists and has been recognized by honor societies including Rho Chi and Gamma Beta Phi.

Reference:

  1. Takanari, J., Sato, A., Waki, H., Miyazaki, S., Uebaba, K., & Hisajima, T. (2018). Effects of AHCC® on immune and stress responses in healthy individuals. Journal of Evidence-Based Integrative Medicine, 23, 2156587218756511.

Comments (0)

Leave a Reply

Back To Top